KRAS and neoplasm: First-line gemcitabine-based treatment was initiated before availability of tumor mutational profiling data, which subsequently showed high-level HER2 DNA copy number amplification (>20 copies), HER2 mRNA overexpression (95+% rank among PDAC cases in the Tempus database), and pathogenic DNA mutations (Table 1), including KRAS G12D (Table 1).